# A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

> **NCT03082300** · PHASE1 · TERMINATED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)
- Epidermal Growth Factor Receptor (EGFR) Mutations

## Interventions

- **DRUG:** naquotinib

## Key facts

- **NCT ID:** NCT03082300
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-24
- **Primary completion:** 2017-05-12
- **Final completion:** 2017-06-19
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082300, "A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT03082300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*